

For Immediate Release

Prof. Salwa A. Elgebaly Celebrated for Dedication to the Field of Cardiovascular Medicine

Prof. Elgebaly founded Nour Heart, Inc. in 2006 to pursue research into heart-related diagnostic and therapeutic products and is a Professor at the University of Connecticut Faculty of Medicine (Adj.), Farmington, Connecticut, U.S.

VIENNA, VA, November 26, 2019, Prof. Salwa Elgebaly has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.



The U.S. Food and Drug Administration (FDA) has recently granted Orphan Drug Designation to [Nour Heart](#)'s new drug Cyclocreatine Phosphate for the *prevention of ischemic injury to enhance cardiac graft recovery and survival in heart transplantation* (DRU-2015-4951).

A research professional in the biomedical field, Prof. Elgebaly excels as the founder and the chief executive officer of Nour Heart, Inc., where she handles research and development for heart-related diagnostic and therapeutic products, conducts clinical trials in pharmaceutical set-up and investigative sites and submits products to the FDA for approval. Her research has resulted in the discovery of the heart-derived inflammatory mediator, Nourin as an *early* laboratory biomarker for the quick diagnosis of heart patients experiencing chest pain, and thus, allowing crucial therapy to save heart muscles. Her research further identified Cyclocreatine Phosphate as a potent cardioprotective drug aimed at protecting heart patients against ischemic injury, and also, the anti-inflammatory agent Cyclosporin H which protects hearts against inflammation-induced injury. Prof. Elgebaly has written a *Review* article on the cardioprotective benefits of Cyclocreatine Phosphate which was published in the *Journal of Expert Review of Cardiovascular Therapy* in September 2019. She is a sole inventor and contributor to nine patents issued by the U.S. Patent Office in Washington DC and, also, inventor on one pending application. Prof. Elgebaly has been the Principal Investigator on 33 research grants totaling nearly \$7 million in funding. Prof. Elgebaly is also the recipient of the 2016 and 2018 “Jesor” grants from the Egyptian Academy of Scientific Research and Technology in conjunction with Cairo University and Helwan University, Cairo, Egypt.

Prof. Elgebaly's work was selected by Expert Panel to appear in the 2013 CardioValens.com under the title: *A new powerful and early marker of myocardial ischemia/reperfusion – cardiac Nourin* and her patent was included in the Immunology Chapter of Dr. Ashton Acton's Scholarly book entitled: *Acute Myocardial Infarction: New Insights for the Health Care Professional*, 2013 Edition.

Prior to founding Nour Heart, she had gained valuable expertise in Nourin technology as the director of the Nourin Pre-clinical and Clinical Development Program, the director of clinical affairs for AnGes, Inc. and the director of clinical trials and research for the Connecticut Multispecialty Group during the early 2000s. Previously, Dr. Elgebaly worked as the director of clinical trials and research for Grove Hills Medical Center from 1998 to 2000, and in numerous educational positions at the University of Connecticut School of Medicine from 1979 to 1997 (Postdoc, Instructor, Assistant Professor, Associate Professor and Director of Surgical Research).

After earning a Bachelor of Science in pharmacy from the University of Alexandria Faculty of Pharmacy in Egypt in 1973, Dr. Elgebaly relocated to the United States in pursuit of higher education. She later completed a postdoctoral fellowship and obtained a Master of Science in oncology and cancer biology at the University of Wisconsin. In 1979, Dr. Elgebaly graduated with a Doctor of Philosophy in oncology and cancer biology at the University of North Carolina, Chapel Hill (ranked number 1 in the world).

A devoted industry and community advocate, Prof. Elgebaly is active as a scientific reviewer for Bibliotheca Alexandria Research Grants and Special Projects and the founder of the *Clinical Research Center (CRC)* at the University of Alexandria Faculty of Medicine to conduct FDA-regulated Clinical Trials. Due to her considerable expertise, she has been invited to speak and function as a consultant on FDA-regulated clinical trials and International Guidelines and Regulations. Likewise, Dr. Elgebaly found success as the chair of the Maryland conference entitled *American Muslim Women* sponsored by *Commissioner for Women* through Anne Arundel County. She also served as a member of the Governor's Commission on Middle Eastern American Affairs, Maryland.

Prof. Elgebaly is a frequent *Invited Speaker* at international cardiology conferences and presented her work in many scientific conferences worldwide including: the American College of Surgeons, American Heart Association, American Association of Immunologists, International Society for Heart Research (ISHR) and Society for Cardiovascular Angiography and Interventions. She has been most honored by invitations to present her unique work from two Nobel Prize Winner in Medicine, Professor Sir John Vane, London, United Kingdom and Professor R. Levi Montalcini, Rome, Italy and Professor Sir Dr. Magdy Yacoub in London, United Kingdom.

Prof. Elgebaly published many peer-reviewed papers in respected journals including: Science, J. Thoracic & Cardiovascular Surgery, J. Molecular and Cellular Cardiology, J. Pathology, J Expert Review of Cardiovascular Therapy, J. Transplantation, J. Urology, J Pharmacology Experimental Therapy, American Journal of National Cancer Institute, and Journal of Ophthalmology and Visual Science and a *Review* article entitled *Cyclocreatine Protects Against Ischemic Injury and Enhances Cardiac Recovery During Early Reperfusion* published in the Journal of Expert Review of Cardiovascular Therapy, 17(9), 683-697, 2019.

Looking toward the future, Prof. Elgebaly intends to continue her work by developing a diagnostic test and medication aimed at helping people prone to heart attacks through early diagnosis and treatment.

About Marquis Who's Who®:

Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Today, Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis® publications may be visited at the official Marquis Who's Who® website at www.marquiswhoswho.com.